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Bother index can be used in deciding how the symptom
nocturia itself is important
Ahmet Tunç ÖZDEMİR1, Hacı İbrahim ÇİMEN1, Serkan ALTINOVA1, Ali Fuat ATMACA2,
Ege Can ŞEREFOĞLU1, Mevlana Derya BALBAY1

Aim: To report the prevalence of nocturia. Associated risk factors and bother in various age groups (by decade) were
evaluated in order to determine the characteristics of individuals who may need medical help.
Materials and methods: To estimate the extent to which patients were bothered relative to nocturia in various age
groups (by decade), a descriptive figure, the “bother index,” was used. The bother index was calculated by dividing the
number of individuals reporting a bother score higher than a symptom score by the number of individuals reporting a
bother score lower than a symptom score in the same age and sex group.
Results: Data from 940 women and 2073 men were analyzed. The overall prevalence of nocturia was 65%, with an
increasing proportion in the older groups in both sexes (P < 0.001). In light of the bother index, nocturia was better
tolerated in women than in men (0.0271 vs. 0.074, respectively), and patients with a higher frequency of nocturia also
reported a higher bother score (P < 0.001). The highest bother index value was seen in the third decade (0.080), and it
decreased as the decades progressed.
Conclusion: Nocturia is better tolerated in women and elderly populations. The bother index may be a useful indicator
of the bother of nocturia and may help in deciding whether an individual with nocturia needs medical help.
Key words: Bother, nocturia, prevalence

“Bother index” noktürinin tek başına ne kadar önemli olduğuna karar vermede
kullanılabilir
Amaç: Tedaviye ihtiyaç duyabilecek bireylere özgü özellikleri tanımlamak için noktürinin prevalansını, ilişkili risk
faktörleri ve dekatlara göre verdiği rahatsızlık.
Yöntem ve gereç: Noktürinin dekatlarda verdiği rahatsızlığı tahmin edebilmek için tanımlayıcı bir model olan “bother
index” kullanıldı. Bother index aynı yaş ve cinsiyet grubundaki bireyler sayısal olarak bölünerek, rahatsızlık skoru
semptom skorundan fazla olan ve rahatsızlık skoru semptom skorundan düşük olanlar şeklide hesaplandı.
Bulgular: 940 bayan 2073 erkekten toplanan veriler analiz edildi. Noktürinin genel prevalansı her iki cinsiyette yaşla
artmakla beraber % 65’ti (P < 0,001). Bother index ışığında noktürinin bayanlarda erkeklere göre daha iyi tolere edildiği
gözlendi (sırası ile 0,0271’e karşı 0,074) ve noktüri sıklığı daha fazla olan hastalar daha yüksek rahatsızlık skoru bildirdi
(P < 0,001). En yüksek “bother index” değeri 3. dekatta görüldü (0,080) ve dekat arttıkça azaldığı izlendi.
Sonuç: Noktüri bayanlarda ve yaşlı bireylerde daha iyi tolere edilir. “Bother index” noktürinin verdiği rahatsızlığı
tahmin etmede yaralı bir belirteç olabilir ve medikal tedaviye ihtiyacı olan noktürili bireyleri saptamada yaralı olabilir.
Anahtar sözcükler: Bother, noktüri, prevalans
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Introduction
With an ageing population, urinary symptoms are
increasingly becoming a major health issue (1).
Nocturia is considered to be the most common lower
urinary tract symptom (LUTS) and is increasingly
recognized as a clinical entity (2). The International
Continence Society (ICS) defines nocturia as “waking
at night to pass urine” and it applies to any number of
voids at any time during the night (3). Current studies
report that nocturia is a common condition in both
sexes, and its prevalence increases with advancing age
(2). Since these studies used different definitions of
nocturia and examined different populations, there
is variation in the reported prevalence of nocturia
among countries and studies (4).
Nocturia seldom occurs in isolation; it has also
been shown to have many different causes and can
be associated with a wide range of diseases. This
implies that the health status of those with nocturia
is probably worse than that of the general population
(5). Additionally, nocturia is a bothersome condition
with a significant effect on quality of life, and the
degree of bother is likely to be associated with the
degree of nocturia. Waking at night can result in
sleep disturbance and fatigue, with a greater risk
of falls and subsequent fractures in the elderly (1).
On the other hand, not all patients with nocturia
are bothered by their condition. This relationship
is probably important in determining whether an
individual with nocturia will seek medical help.
The Danish Prostatic Symptom Score (DANPSS-1) questionnaire was published by Hansen et
al. in 1991, and, at that time, it contained a unique
feature: not only occurrence but also the bother of the
symptom was judged at the same time by the subject.
Although correlation of symptom score with bother
score has been found to be good in both scoring
systems, the symptom and bother questions do not
collect the same information, and the variability
between the 2 scales has been high (6,7). These
differences mean that both symptom and bother
questions are needed in the same questionnaire
intended for clinical use or epidemiologic studies,
considering not only prevalence but also the impact
of nocturia in a population.
The aim of this study was to report the prevalence
of nocturia, its associated risk factors, and its
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impact on bother in various age groups (by decade),
in order to quantify and evaluate the bother of
nocturia in relation to its severity and determine the
characteristics of individuals who may need medical
help.
Materials and methods
Between December 2006 and May 2007, attendants
of nonurologic patients in our hospital, older than
20 years, were asked to participate in our study and
were interviewed directly when they accepted. The
Turkish translation of the DAN-PSS-1 questionnaire
was used in assessing nocturia/LUTS in the study
population. The DAN-PSS-1 questionnaire was
delivered to the volunteers in assessing nocturia
as well as other lower urinary tract symptoms (8).
Responses to the nocturia questions from the DANPSS-1, “How many times did you have to urinate
during the night for the past 2 weeks?” and “How
much of a problem was getting up to urinate during
the night for you?”, were specifically evaluated in our
cohort for the present study.
Nocturia was rated from 0 to 3 with increasing
frequency or severity (symptom score), and its
impact on daily life was also recorded as a bother
score. For the bother score, 0 was considered as no
bother, and the other grades reflected perceived small
(score of 1), moderate (score of 2), or severe (score
of 3) problems. Concomitant medical conditions
including hypertension (HT), diabetes mellitus
(DM), cardiovascular disease (CVD), renal disease
or neurological disorder (ND), and benign prostatic
hyperplasia (BPH), based on patient history, were
also noted.
To estimate bother relative to nocturia, a
descriptive figure, the bother index (BI), was used
for each group. The BI was calculated by dividing
the number of volunteers in that age group reporting
a bother score higher than a symptom score by the
number of others reporting a bother score lower
than a symptom score. A low BI was considered to
describe a symptom that was tolerable or innocuous,
whereas a high BI was considered to describe a
symptom that was annoying at any symptom score
level. The responses in which symptoms and bother
scores were equal provided no information for the BI
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since these were insensitive to the prevalence of the
symptom.
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The data were analyzed using SPSS 10.0 (SPSS Inc,
Chicago, IL, USA). The prevalence of nocturia with
regard to sex, age group, presence of DM, presence of
HT, coronary arterial disease, BPH, renal disease, and
stroke was compared between groups using the chisquare test. The association between the risk factors
and nocturia prevalence was determined by using
logistic regression analysis. Statistical significance
was set at 0.05.
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Figure. A plot of the percentages of individuals in different age
groups (years) who reported nocturia.

Results
The 3013 responders were included. The mean age
of the subjects was 44.9 ± 16.5 (median: 45) years,
of whom 68.8% were male (Table 1). The overall
prevalence of nocturia (more than 1 void/night on
average) in the Turkish adult population was 65%. Of
this population, 37.3% woke once to void at night,
26.7% woke twice to void at night, and 35.9% woke
3 or more times. Of the men, 67.3%, and of the
women, 59.7% reported having nocturia, which was a
statistically significant difference between the groups
(P < 0.001). Additionally, the prevalence of nocturia
increased with increasing age; it was lowest in the 2029 age group (30.7% in males, 28.1% in females) and
the highest at and after the age of 70 in both groups
(92.7% in males, 89.7% in females) (Figure).

In the univariate analysis, in addition to sex and
age group, the nocturia prevalence was affected by the
presence of DM, HT, CVD, BPH, renal diseases, and
ND; there was not a statistically significant relation
between smoking and nocturia (data not shown).
In the logistic regression analyses performed
using the factors found to be associated with nocturia,
the risk of nocturia was determined to be 1.4 times
higher in males than in females (OR = 1.454; 95%
CI = 1.229-1.721). The presence of DM increased the
risk by 1.05 times, whereas HT increased the risk by

Table 1. The demographic data of individuals with and without nocturia.
Nocturia
% (n)

No nocturia
% (n)

BI

Total
N

Male

67.3 (1395)

32.7 (678)

0.074

2073

Female

59.7 (561)

40.3 (379)

0.027

940

2nd

28.9 (221)

71.1 (543)

0.060

764

3rd

53.5 (259)

46.5 (225)

0.080

484

4th

74.3 (391)

25.7 (135)

0.049

526

5th

82.1 (439)

17.9 (96)

0.075

535

6th

91.7 (421)

8.3 (38)

0.040

459

≥7th

92.2 (226)

7.8 (19)

0.053

245

Sex

Decade
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Table 3 shows the percentage of individuals
waking at different times in the night with different
degrees of bother. There was a significant association
between more voids at night and an increasing degree
of bother (P < 0.001).

1.1 times, CVD by 1.2 times, BPH by 1.1 times, and
renal diseases by 2.7 times. The risk of nocturia was
2.1 times higher in those who had a history of stroke
or any other ND than in those who did not (OR =
2.109; 95% CI = 1.515-2.935) (Table 2).

Table 2. Logistic regression analysis of the factors affecting nocturia prevalence.
n (%)*
Age

Β

OR (95% CI)

P

0.078

1.081 (1.074-1.088)

<0.001

0.374

1.454 (1.229-1.721)

<0.001

1.054

2.870 (1.971-4.180)

<0.001

1.157

3.179 (2.390-4.229)

<0.001

1.238

3.448 (2.046-5.811)

<0.001

1.145

3.141 (1.930-5.811)

<0.001

0.994

2.701 (1.169-6.242)

<0.001

0.746

2.109 (1.515-2.935)

<0.001

Sex
Female

940 (59.7)

Male

2073 (67.3)

DM
Absent

2748 (62.8)

Present

265 (86.8)

Absent

2563 (61.3)

Present

450 (85.8)

HT

CVD
Absent

2859 (69.7)

Present

154 (89.0)

BPH
Absent

2857 (63.7)

Present

156 (87.1)

Renal diseases
Absent

2974 (64.7)

Present

39 (82.1)

Absent

2781 (63.9)

Present

232 (78.0)

ND

*Prevalence of nocturia

Table 3. The association between the degree of nocturia and bother.
Bother score
0

Nocturia

1

2

3

Total

%x

%xx

%x

%xx

%x

%xx

%x

%xx

n

1

64.2

71.9

30.8

39.7

4.5

9.0

0.4

0.8

730

2

25.0

20.1

42.8

39.5

25.4

36.4

6.7

9.4

523

≥3

7.4

8.0

16.8

20.8

28.3

54.5

47.5

89.7

703

n

652

567

%x: row percentage; %xx: column percentage; χ2 = 2858,927; P < 0.0001.
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Discussion
Nocturia is one of the most common urological
symptoms in both men and women, and its
prevalence increases with advancing age (1). It is
reported as the second most bothersome symptom
that has severe impact on the health-related quality of
life (9). Although the ICS defines nocturia as “waking
at night to pass urine”, which applies to any number
of voids at any time during the night, the previously
unstandardized definition of nocturia resulted in
different prevalence rates from different study groups
(2,3). Tikkinen et al. reported the age-standardized
prevalence of nocturia as approximately 40% in
Finland and stated that nocturia was more common
among young women than men (10).
We observed a similar prevalence among young
individuals, whereas the prevalence rate in men
exceeded its rate in women after the age of 60 in
our study (Figure). The prevalence rate of nocturia,
defined as waking up to pass urine at least once
nightly, was 65% (59.7% in women, 67.3% in men)
in the present study, whereas 40.6% reported voiding
at least twice nightly. In respect to these results, the
prevalence of nocturia in Turkey seems to be slightly
higher than that of most other countries. This
difference may be due to the inclusion of both men
and women, without age limits or social factors and
habits. Although there was a lower prevalence among
women in the present study, other studies have not
confirmed this (3,11). However, those studies were
not based on a representative study population and
they defined nocturia as at least 2 voids per night, the
definition that was commonly used before 2002.
It is clear that nocturia is not an isolated entity but
is also associated with other diseases. Hence, it may
be worthwhile for physicians to screen patients with
associated medical conditions or voiding symptoms
for nocturia. The increase in nocturia may also be
associated with other mechanisms that show an
increased occurrence in the elderly compared to
younger individuals and may not necessarily be
linked to age. Poor health is increasing in parallel
with increasing age, and there is an increase in
nocturia in men with poor health (12,13). Our study
confirmed the association between nocturia and
other medical conditions such as DM, HT, BPH,
CVD, renal diseases and strokes, or other NDs (Table

2). Interestingly, renal diseases and neurological
symptoms were not the most significant correlates
of nocturia symptoms, as was noted in a study by
Liew et al. (11). In that study, subjects self-identified
their medical conditions; that could have led to an
underestimation of the prevalence of these diseases
in their study and this could be a possible reason for
this difference.
The prevalence of nocturia increases with age.
Nocturnal polyuria due to age-related changes in
the circadian regulation of urine production has
been considered to be among the primary causes of
nocturia, accounting for up to 70% of cases (14,15).
The mean voided volume decreases significantly
with age as a result of diminished functional bladder
capacity, changes in bladder morphology, progressive
denervation, and hypertrophy of the bladder wall
caused by obstruction and/or an overactive bladder
(16,17). The present study supports this, as shown by
an increase in the prevalence of nocturia with age; it
increased from 28.9% in the third decade to 92.2%
in the eighth decade and beyond. The symptom of
nocturia is strongly associated with BPH and our
study showed a similar relationship, although Homma
et al. suggested that nocturia is the least specific of
all of the symptoms associated with BPH and the
least sensitive related to treatment (18). In addition
to that, there may be some functional changes in the
ageing bladder, which results in either a bladder of
smaller capacity or a decrease in bladder compliance.
Therefore, it is important to use an algorithmic
approach to elucidate the cause of nocturia in the
elderly, rather than viewing nocturia as a natural part
of ageing (4).
There are many simple prevalence studies
of nocturia; there is a need for more advanced
epidemiological analysis of risk factors and
comorbidity using multivariate techniques to
further address questions regarding cofactors and
predictors for nocturia. When evaluating analytical
epidemiological data, it is important to define
“normal” and to distinguish between perceptions of
symptoms and clinical entities. To maintain a more
clinical approach, analytical measures should be
combined with a secondary measure such as quality
of life, bother, or a clinically relevant symptom score.
Epidemiological data are prone to being misused
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because associations often have been misinterpreted
as causes (19).
A fundamental goal for developing scoring
systems for nocturia has been needed to quantify
and find objective support in decision-making for
nocturia treatment. Although the correlation of
symptom score with bother score has been found
to be good in some other studies, the symptom and
bother questions do not collect the same information
and the variability between these 2 scales has been
high (7,20). The DAN-PSS-1 scoring system is based
on the frequency or severity of urinary symptoms
and on their influence on daily life and bother (8).
The simple mathematical approach used in this
study, the BI, reflects the relative importance of
bother to symptom simultaneously in the same group
of patients. We evaluated the perceived bother of
nocturia in a population-based sample and compared
it within different sex and age groups by means
of the BI. In respect to the BI results, we observed
that nocturia is considered more bothersome in the
young, although it is more prevalent in older age
groups. Additionally, women seem to be less bothered
by nocturia than men (Table 1).
The nocturnal voiding frequency is another
important factor in determining whether a patient
with nocturia is likely to be bothered by it and seek
medical help. In general, the proportion of people
considering nocturia to be a problem increases with

its frequency. The degree of bother increases with 2
or more voids at night. A study performed on 2075
British women showed that 63% who had to void
during the night found this to be at least a bit of a
problem (21). In another study, 24% of women who
had 1 or 2 voids/night considered this as a problem
(2). Only 8% of the individuals in a Dutch population
and 9.5% of an Asian population felt bothered by 1
void/night (4,11). In our study, 64.2% of the patients
did not see 1 episode of voiding at night as a problem.
Therapy for nocturia must be initiated according
to the degree of bother. Therefore, appropriate scores
quantifying the bother of nocturia/LUTS are required
to evaluate the need for treatment of BPH from the
patient’s perspective. Bother is very important as a
symptom score, especially in decision-making among
treatment options. We believe that the BI might be
used as a more objective criterion, not only to make
such a decision in the management, but also for
assessing the results of treatment modalities such as
watchful waiting and medical or surgical treatment.
Nocturia is a common condition in both men
and women, especially in the elderly. It has a strong
association with poor health status. Although the
degree of nocturia determines whether patients are
likely to be bothered, the BI may be a useful indicator
of the bother of nocturia and may help in determining
whether an individual with nocturia needs medical
help.
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